FDA Approves Botox Competitor Dysport / Reloxin!
BIG news in the plastic surgery field. The FDA approved the drug Dysport (otherwise known as Reloxin) today for the treatment of fine lines in the glabella (between the brows). This is the first bona-fide competitor to Botox, as it is also a Botulinum Toxin Type A. I’ve mentioned Reloxin in this blog before, as […]
- Posted on: Apr 30 2009